Top 5 Drug Type | Count |
---|---|
Fusion protein | 3 |
Nanobody | 3 |
Monoclonal antibody | 2 |
Biosimilar | 2 |
Antibody drug conjugate (ADC) | 1 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date24 Nov 2021 |
Target |
Mechanism HER2 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TFPI inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Sep 2025 |
Sponsor / Collaborator |
Start Date02 Aug 2024 |
Sponsor / Collaborator |
Start Date02 Aug 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Armocibart ( TFPI ) | Hemophilia A More | Phase 3 |
Envafolimab ( PDL1 ) | Metastatic gallbladder cancer More | Phase 3 |
Anbenitamab repodatecan ( HER2 x Top I ) | HER2-Low Breast Carcinoma More | Phase 3 |
Bevacizumab biosimilar(Suzhou Alphamab) ( VEGF-A ) | Colorectal Cancer More | Phase 3 |
Lofacimig ( FXIa ) | Venous Thromboembolism More | Phase 2 |